—Aktis launches with $72 million for cancer radiotherapy “” Aktis Oncology has launched with $72 million in series A financing to develop radiopharmaceuticals for cancer. The start-up was founded and incubated by the venture capital firm MPM Capital. Aktis is developing targeted therapies that use α-particle-emitting radioisotopes to kill cancer cells.
by Michael McCoy | March 20, 2021
/pharmaceuticals/oncology/Amgen-acquire-Five-Prime-19/99/i9 20210312 Concentrates 99 9 /magazine/99/09909.html Amgen to acquire Five Prime for $1.9 billion oncology, pharmaceuticals con bus Ryan Cross pharmaceuticals oncology business mergers-&-acquisitions Amgen to acquire Five Prime for $1.9 billion Chemical & Engineering News Amgen to acquire Five Prime for $1.9 billion Amgen to acquire Five Prime for $1.9 billion
by Ryan Cross | March 12, 2021
/pharmaceuticals/oncology/Teon-raises-30-million-cancer/99/i8 20210305 Concentrates 99 8 /magazine/99/09908.html Teon raises $30 million for cancer drugs pharmaceuticals, oncology, teon con bus Ryan Cross pharmaceuticals oncology business start-ups Teon raises cash for cancer drugs Chemical & Engineering News Teon raises $30 million for cancer drugs Teon raises $30 million for cancer drugs
by Ryan Cross | March 05, 2021
/pharmaceuticals/oncology/One-on-one-with-Kimberly-M-Jackson/99/i6 20210222 Grad student Kolade Olayiwola Adebowale talks with this chemist about her work to treat prostate cancer 99 6 /magazine/99/09906.html One on one with Kimberly M. Jackson Oncology, Kimberly M. Jackson, Kolade Olayiwola Adebowale, food science scitech Kolade Olayiwola Adebowale, special to C&EN pharmaceuticals oncology Kimberly M.
by Kolade Olayiwola Adebowale, special to C&EN | February 22, 2021
The team is working on projects in oncology focused on understanding the genetics of cancer and the fundamentals of how cancer cells behave. It is also exploring immunology, including inflammatory diseases like psoriasis. Akinsanya is not only an exceptional scientist, according to Schrödinger president and CEO Ramy Farid.
by Makeda Easter, special to C&EN | February 22, 2021
You would essentially make the disease’s symptoms completely go away,” says Stuart Orkin, a pediatric hematology-oncology researcher at Harvard Medical School whose lab Dassama worked in before coming to Stanford. Though there are gene therapy approaches for sickle cell disease, those treatments are expensive and may not be as widely accessible.
by Nicholas St. Fleur, special to C&EN | February 22, 2021
/business/investment/Dana-Farber-Deerfield-launch-Riverway/99/i6 20210222 Concentrates 99 6 /magazine/99/09906.html Dana-Farber and Deerfield launch Riverway Discoveries investment, pharmaceuticals, oncology, deerfield, dana-farber con bus Ryan Cross business investment pharmaceuticals oncology Dana-Farber launches R&D firm with Deerfield Chemical & Engineering News Dana-Farber and Deerfield launch Riverway Discoveries Dana-Farber and Deerfield launch Riverway Discoveries
by Ryan Cross | February 22, 2021
The drug company will pay $60 million up front and up to $785 million overall to use Gritstone Oncology’s cancer vaccine platform to develop therapeutic vaccines for HIV. The vaccines would not prevent HIV infection but rather spur the immune system to kill off infected cells. A therapeutic vaccine could be an important part of what’s known as the kick-and-kill strategy for curing HIV, says Diana Brainard, head of Gilead’s viral therapeutics group.
by Megha Satyanarayana | February 03, 2021
/pharmaceuticals/oncology/Lilly-licenses-Merus-antibody-therapy/99/i3 20210123 Concentrates 99 3 /magazine/99/09903.html Lilly licenses Merus antibody therapy for up to $1.6 billion biologics, antibodies, cancer con bus Megha Satyanarayana pharmaceuticals oncology business investment Lilly to license Merus antibody therapy Chemical & Engineering News Lilly licenses Merus antibody therapy for up to $1.6 billion Lilly licenses Merus antibody therapy for up to $1.6 billion
by Megha Satyanarayana | January 23, 2021
/business/start-ups/Dana-Farber-launches-own-venture/99/i3 20210123 Concentrates 99 3 /magazine/99/09903.html Dana-Farber launches its own venture fund business, startups, pharmaceuticals, oncology con bus Ryan Cross business start-ups pharmaceuticals oncology Dana-Farber forms its own venture fundBoston’s Chemical & Engineering News Dana-Farber launches its own venture fund Dana-Farber launches its own venture fund
by Ryan Cross | January 23, 2021